We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Manufacturers racing to build what could be one of industry’s biggest markets must tread with care
In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide
Clinical study results could boost patient access to new class of treatment
US pharma group’s late-stage study has shown treatment can slash body weight by nearly a sixth
Corporate America faces its sharpest drop in profits since the beginning of the Covid pandemic
Chief executive says draft plan to cut market exclusivity protection could make pursuing some treatments unviable
Pharma group’s decision comes in response to US political pressure over high cost of diabetes medication
AbbVie and Eli Lilly take action after clawback payments on branded drugs reach a quarter of UK sales
Eli Lilly, Amgen, Pfizer and Regeneron follow Novo Nordisk into obesity treatments worth billions
From obesity drugs to cancer treatments, this year should be remembered for pharmaceutical advances
Chief executive claims Republican state government ‘rushed’ process when passing sweeping restrictions
Verge says ALS therapy is one of the first to be developed by a tech-enabled platform
Pharmaceutical company says new legislation will hinder its ability to attract diverse talent
On paper the obesity drug market is huge but mass adoption of the treatments would strain health budgets
Late-stage trial of Tirzepatide could be a ‘potential breakthrough’ in treatment, says US drugmaker
Pharma executive warns policymakers may be incapable of preparing the public for next pandemic
Hypothesis that brain plaques cause disease viewed with scepticism by some scientists
US drugmaker says independent probe was sparked by claims of a personal relationship with an employee
Studies suggest antibody therapies are less effective against new variants
Failure rate has been dauntingly high but success would be hugely profitable
US FDA gives emergency approval to bamlanivimab therapy designed to boost immune system
Johnson & Johnson and Eli Lilly announce pauses in blow to hopes for pandemic remedy
Early signs are promising but there will be limits on how much the drug companies can charge
Antibody would be one of first treatment options for patients with mild or moderate illness
Setback deals another blow to most common hypothesis about causes of the disease
International Edition
